Related Experiment Video
Updated: Aug 21, 2026
The Dimethylnitrosamine Induced Liver Fibrosis Model in the Rat
Published on: June 17, 2016
Peroxisome proliferator-activated receptor gamma ligands suppress liver carcinogenesis induced by diethylnitrosamine
Yan-Tong Guo1, Xi-Sheng Leng, Tao Li
1Department of General Surgery, Beijing Jishuitan Hospital, the Forth Clinical Medical College of Peking University, Beijing 100035, China. guoyantong2002@sohu.com
Aim:
Peroxisome proliferator-activated receptor gamma (PPARgamma) is known to regulate growth arrest and terminal differentiation of adipocytes and is used clinically as a new class of antidiabetic drugs. Recently, several studies have reported that treatment of cancer cells with PPARgamma ligands could induce cell differentiation and apoptosis, suggesting a potential application as chemopreventive agents against carcinogenesis. In the present study, 3 different kinds of PPARgamma ligands were subjected to the experiments to confirm their suppressive effects on liver carcinogenesis.
Methods:
Three PPARgamma ligands, pioglitazone (Pio) (200 ppm), rosiglitazone (Rosi) (200 ppm), and troglitazone (Tro) (1,000 ppm) were investigated on the induction of the placental form of rat glutathione S-transferase (rGST P) positive foci, a precancerous lesion of the liver, and liver cancer formation using a diethylnitrosamine-induced liver cancer model in Wistar rats, and dose dependency of a PPARgamma ligand was also examined.
Results:
PPARgamma ligands reduced the formation of rGST P-positive foci by diethylnitrosamine and induction of liver cancers was also markedly suppressed by a continuous feeding of Pio at 200 ppm.
Conclusion:
PPARgamma ligands are potential chemopreventive agents for liver carcinogenesis.
Insights
Peroxisome proliferator-activated receptor gamma (PPARgamma) ligands show promise in preventing liver cancer. Studies found these compounds significantly reduced precancerous lesions and liver cancer formation in rats.
Area of Science:
- Hepatology
- Oncology
- Pharmacology
Background:
- Peroxisome proliferator-activated receptor gamma (PPARgamma) regulates adipocyte differentiation and is a target for antidiabetic drugs.
- Emerging research suggests PPARgamma ligands may possess chemopreventive properties against various cancers by inducing cell differentiation and apoptosis.
- This study investigates the potential of PPARgamma ligands in suppressing liver carcinogenesis.
Purpose of the Study:
- To evaluate the chemopreventive effects of three PPARgamma ligands against diethylnitrosamine-induced liver carcinogenesis in Wistar rats.
- To assess the impact of PPARgamma ligands on the formation of precancerous lesions (rGST P-positive foci) and liver cancer development.
- To examine the dose-dependent effects of a PPARgamma ligand on liver cancer prevention.
Main Methods:
- Three PPARgamma ligands—pioglitazone (Pio), rosiglitazone (Rosi), and troglitazone (Tro)—were administered to rats.
- A diethylnitrosamine-induced liver cancer model was employed to assess the formation of rGST P-positive foci and liver tumors.
- Dose dependency of PPARgamma ligand efficacy was investigated.
Main Results:
- PPARgamma ligands significantly reduced the number of diethylnitrosamine-induced rGST P-positive foci.
- Continuous feeding of pioglitazone (200 ppm) markedly suppressed liver cancer induction.
- The study demonstrated a suppressive effect of PPARgamma ligands on liver carcinogenesis.
Conclusions:
- PPARgamma ligands exhibit potential as chemopreventive agents for liver cancer.
- The findings support the therapeutic application of PPARgamma ligands in reducing liver carcinogenesis.
- Further research into PPARgamma ligands for cancer prevention is warranted.
Related Concept Videos
01:31Transducer Mechanism: Nuclear Receptors
About 48 different soluble family members of nuclear receptors are identified that can be divided into two main classes:
01:25Mutagenicity and Carcinogenicity
01:24Peroxisomes